At a glance
- Originator Kino Pharma
- Developer Kino Pharma; Kyoto University
- Class Amides; Antineoplastics; Antivirals; Fluorinated hydrocarbons; Organic sulfur compounds; Piperidines; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Cyclin dependent kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cervical intraepithelial neoplasia; Warts
Most Recent Events
- 04 Nov 2020 Phase-II clinical trials in Cervical intraepithelial neoplasia in Japan (unspecified route) (Kino Pharma pipeline, November 2020)
- 04 Nov 2020 Phase-II clinical trials in Cervical intraepithelial neoplasia in South Korea (unspecified route) (Kino Pharma pipeline, November 2020)
- 27 Oct 2020 Phase-I clinical trials in Cervical intraepithelial neoplasia in Japan (unspecified route) (Kino Pharma pipeline, October 2020)